Hans Urban

Dr. Senckenberg Institute Of Neurooncology
Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Targeting glioblastoma mitochondrial metabolism with S-Gboxin induces cytotoxicity under conditions of the tumor microenvironment.

Targeting glioblastoma mitochondrial metabolism with S-Gboxin induces cytotoxicity under conditions of the tumor microenvironment.

Journal: Cell death discovery
Published: August 27, 2025

Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma.

Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma.

Journal: Cell death discovery
Published: August 18, 2025

AMP-activated protein kinase mediates adaptation of glioblastoma cells to conditions of the tumor microenvironment.

AMP-activated protein kinase mediates adaptation of glioblastoma cells to conditions of the tumor microenvironment.

Journal: Journal of experimental & clinical cancer research : CR
Published: December 27, 2024

Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients.

Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients.

Journal: Acta neuropathologica communications
Published: August 29, 2024

An AMP-activated protein kinase-PGC-1α axis mediates metabolic plasticity in glioblastoma.

An AMP-activated protein kinase-PGC-1α axis mediates metabolic plasticity in glioblastoma.

Journal: Clinical and translational medicine
Published: April 09, 2024

Superoxide dismutase 1 mediates adaptation to the tumor microenvironment of glioma cells via mammalian target of rapamycin complex 1.

Superoxide dismutase 1 mediates adaptation to the tumor microenvironment of glioma cells via mammalian target of rapamycin complex 1.

Journal: Cell death discovery
Published: March 28, 2024

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1.

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1.

Journal: Cells
Published: February 21, 2024

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review.

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review.

Journal: Neurological research and practice
Published: February 05, 2024

Feasibility and comparability of different platelet function tests in acute stroke with or without prior antiplatelet therapy.

Feasibility and comparability of different platelet function tests in acute stroke with or without prior antiplatelet therapy.

Journal: Frontiers in neurology
Published: December 26, 2023

Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death.

Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death.

Journal: Cell death discovery
Published: May 19, 2023

Prevalence of acute neurological complications and pathological neuroimaging findings in critically ill COVID-19 patients with and without VV-ECMO treatment.

Prevalence of acute neurological complications and pathological neuroimaging findings in critically ill COVID-19 patients with and without VV-ECMO treatment.

Journal: Scientific reports
Published: June 04, 2022

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.

Journal: Journal of neuro-oncology
Published: March 17, 2022
Showing 1-12 of 24

Last Updated: 09/26/2026